Neurimmune
CompanySwitzerland
Neurimmune develops one asset, in phase 2 (ALXN2220 in amyloid transthyretin cardiomyopathy). Mostly antibody acting on proteostasis and TTR; based in Switzerland.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Binds misfolded transthyretin and promotes immune-mediated clearance of cardiac amyloid deposits.
Phase 2, Antibody, Proteostasis, TTR, amyloid transthyretin cardiomyopathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals2
- Similar companies6